 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

We can readily understand why investors are attracted to unprofitable companies. For example, although...

We're Not Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn

Apogee Therapeutics, Inc. (NASDAQ:APGE  Free Report)  Equities research analysts at Wedbush cut their FY2023 EPS estimates for shares of Apogee Therapeutics in a report released on...

FY2023 EPS Estimates for Apogee Therapeutics, Inc. (NASDAQ:APGE) Reduced by Analyst

Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE  Get Free Report) have earned an average rating of Buy from the six ratings firms that are covering the firm, MarketBeat reports...

Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives $34.40 Consensus PT from Analysts

Phase 1 clinical trial of APG777, a fully optimized, subcutaneous, extended half-life anti-IL-13 antibody, initiated ahead of schedule with initial PK and safety data from healthy volunteers expected...

Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results

SAN FRANCISCO and WALTHAM, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the...

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

Apogee Therapeutics, Inc. (NASDAQ:APGE  Get Free Report)s share price hit a new 52-week low on Friday . The stock traded as low as $14.73 and last traded at $14.80, with a volume of...

Apogee Therapeutics (NASDAQ:APGE) Sets New 1-Year Low at $14.73

Apogee Therapeutics, Inc. (NASDAQ:APGE  Get Free Report) has been assigned a consensus rating of Buy from the six brokerages that are covering the firm, MarketBeat reports. Six...

Apogee Therapeutics, Inc. (NASDAQ:APGE  Get Free Report) shares saw an uptick in trading volume on Monday . 256,093 shares traded hands during mid-day trading, a decline of 14% from the...

Apogee Therapeutics (NASDAQ:APGE) Sees Large Volume Increase

SAN FRANCISCO, CA and WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the...

Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress

Apogee Therapeutics, Inc. (NASDAQ:APGE  Get Free Report) shares dropped 3.7% during trading on Wednesday . The company traded as low as $20.03 and last traded at $20.03. Approximately 1,471...

Apogee Therapeutics (NASDAQ:APGE)  Shares Down 3.7%

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in February 2022 and is headquartered in Waltham, MA.

Watchers	14
52-Wk Low	$14.19
52-Wk High	$25.54

Market Cap	$871.6M
Volume (M)	329,489.00
52-Wk High	$25.54
52-Wk Low	$14.19

Current Price	$16.86
Prev Close	$17.20
Open	$17.11
Dividend Yield	N/A
50-Day Moving Average	$18.84
Beta	0.00
Avg. Volume	311,106.00
PE Ratio	N/A

52-Week High	$25.54
52-Week Low	$14.19
Market Capitalization	$871.6M
EPS	N/A
Price to Book	2.09
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

APGE Apogee Therapeutics

About

Feed

News

Sentiment

Fundamentals